MOUNTAIN VIEW, Calif., May 1,
2012/PRNewswire/ -- MAP Pharmaceuticals, Inc.
(Nasdaq: MAPP) today announced that the Company will
participate in the following investor conferences in
Deutsche Bank 37th Annual Healthcare Conference
Tuesday, May 8, at 8:40 a.m. ETin
Bank of America Merrill Lynch 2012 Healthcare
Tuesday, May 15, at 3:40 p.m.
PTin Las Vegas
A live webcast of each event will be available on the
Investor Relations section of MAP Pharmaceuticals'
website at http://www.mappharma.com. A
replay also will be available within 24 hours for seven
days following each presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused
on developing and commercializing new therapies to address
undermet patient needs in neurology. The Company is
developing LEVADEX®, an orally inhaled investigational drug
for the potential acute treatment of migraine. The U.S.
Food and Drug Administration reviewed the New Drug
Application for LEVADEX and on March 26, 2012,
the Company received a Complete Response letter. MAP
Pharmaceuticals has entered into a collaboration agreement
with Allergan, Inc. to co-promote LEVADEX to neurologists
and pain specialists in the U.S. and Canada.
The Company also applies its proprietary drug particle and
inhalation technologies to generate new pipeline
opportunities by enhancing the therapeutic benefits of
proven drugs, while minimizing risk by capitalizing on
their known safety, efficacy and commercialization
history.MAP Pharmaceuticals can be found at http://www.mappharma.com.
MAP Pharmaceuticals, Inc.
SOURCE MAP Pharmaceuticals, Inc.